ONCAlert | 2017 San Antonio Breast Cancer Symposium

The Promise of Olaparib for the Treatment of HER2-Negative Breast Cancer

Alexandra S. Zimmer, MD
Published Online:11:30 AM, Tue June 27, 2017

Alexandra S. Zimmer, MD, staff clinician, Women's Malignancies Branch, National Cancer Institute Center for Cancer Research, discusses the promising data seen thus far with olaparib (Lynparza) for the treatment of HER2-negative breast cancer.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.